Intelligent Bio Solutions Files 8-K
Ticker: INBS · Form: 8-K · Filed: Nov 26, 2024 · CIK: 1725430
Sentiment: neutral
Topics: 8-K, regulatory-filing, financial-statements
TL;DR
Intelligent Bio Solutions filed an 8-K on Nov 26, 2024, with financial and regulatory updates.
AI Summary
Intelligent Bio Solutions Inc. filed an 8-K on November 26, 2024, reporting on Regulation FD disclosures and financial statements. The company, formerly known as GBS Inc., is incorporated in Delaware and has its principal executive offices in New York City.
Why It Matters
This filing provides important updates and disclosures regarding the company's financial status and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, indicating standard corporate reporting rather than a specific event with immediate high risk.
Key Players & Entities
- Intelligent Bio Solutions Inc. (company) — Registrant
- GBS Inc. (company) — Former company name
- Glucose Biosensor Systems (Greater China) Holdings, Inc. (company) — Former company name
- November 26, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Regulation FD disclosures and to provide financial statements and exhibits.
What was Intelligent Bio Solutions Inc. formerly known as?
Intelligent Bio Solutions Inc. was formerly known as GBS Inc. and prior to that, Glucose Biosensor Systems (Greater China) Holdings, Inc.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 26, 2024.
In which state is Intelligent Bio Solutions Inc. incorporated?
Intelligent Bio Solutions Inc. is incorporated in Delaware.
What is the business address of Intelligent Bio Solutions Inc.?
The business address of Intelligent Bio Solutions Inc. is 135 West 41st Street, 5th Floor, New York, NY 10036.
Filing Stats: 519 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-11-26 17:15:10
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value INBS The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 36KB
- ex99-1.htm (EX-99.1) — 16KB
- 0001493152-24-047842.txt ( ) — 230KB
- inbs-20241126.xsd (EX-101.SCH) — 3KB
- inbs-20241126_lab.xml (EX-101.LAB) — 33KB
- inbs-20241126_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 26, 2024, Intelligent Bio Solutions Inc. (the "Company") issued a press release (the "Press Release") announcing the successful completion of its method comparison study on its Intelligent Fingerprinting Drug Screening System. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing disclosure is qualified in its entirety by the full text of the Press Release. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for the purpose of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference. Item 9.01 Financial Statements and Exhibits. No. Description 99.1 Press release dated November 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 26, 2024 INTELLIGENT BIO SOLUTIONS INC. By: /s/ Spiro Sakiris Name: Spiro Sakiris Title: Chief Financial Officer